FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation

Trends in Pharmacological Sciences

Volumn 21, Issue 2, 2000, Pages 49-52

  Brinkmann, Volker ^a   Pinschewer, Daniel ^b   Chiba, Kenji ^c   Feng, Lilli ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^c Yoshitomi Pharmaceutical Industries Ltd   (Japan)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CYCLOSPORIN A; FINGOLIMOD; LEFLUNOMIDE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THERMOZYMOCIDIN;

B LYMPHOCYTE; DRUG ACTIVITY; EFFECTOR CELL; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TRANSPLANTATION;

EID: 0034142317     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(99)01419-4     Document Type: Short Survey

References (30)

1. Adachi K.et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg. Med. Chem. Lett. 5:1995;853-856.
2. Fujita T.et al. Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity. Bioorg. Med. Chem. Lett. 5:1995;847-852.
3. Fujita T.et al. Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols. J. Med. Chem. 39:1996;4451-4459.
4. Fujita T.et al. 2-Substituted 2-aminoethanol: minimum essential structure for immunosuppressive activity of ISP-I (myriocin). Bioorg. Med. Chem. Lett. 5:1995;1857-1860.
5. Chiba K.et al. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with CsA in rats. Transplant. Proc. 28:1996;1056-1059.
6. Yanagawa Y.et al. FTY720, a novel immunosuppressant possessing unique mechanisms. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J. Immunol. 160:1998;5493-5499.
7. Hwang M.-W.et al. FTY720, a new immunosuppressant, promotes long term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation. 100:1999;1322-1329.
8. Suzuki S.et al. Immunosuppressive effect of a new drug, FTY720, on lymphocyte responses in vitro and cardiac allograft survival in rats. Transplant. Immunol. 4:1996;252-255.
9. Hoshino Y.et al. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporin A. Transplant. Proc. 28:1996;1060-1061.
10. Suzuki S.et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 61:1996;200-205.
11. Kawaguchi T.et al. FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporin A. Transplant. Proc. 28:1996;1062-1063.
12. Chiba K.et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160:1998;5037-5044.
13. Troncosco P.et al. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine. Transplantation. 67:1999;145-151.
14. Wang M.E.et al. Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus. Transplantation. 65:1998;899-905.
15. Stepkowski S.M.et al. Synergistic interaction of FTY720 with cyclosporin or sirolimus to prolong heart allograft survival. Transplant. Proc. 30:1998;2214-2216.
16. Mitsusada M.et al. Prevention of graft rejection and graft-versus-host reaction by a novel immunosuppressant, FTY720, in rat small bowel transplantation. Transpl. Int. 10:1997;343-349.
17. Suzuki K.et al. Prevention of experimentally induced autoimmune type I diabetes in rats by the new immunosuppressive reagent FTY720. Transplant. Proc. 30:1998;1044-1045.
18. Chen J.K.et al. The identification of myriocin-binding proteins. Chem. Biol. 6:1999;221-235.
19. Brinkmann V.et al. FTY720 suppresses immune responses by modulating G-protein coupled receptors on lymphocytes resulting in altered lymphocyte homing. Transplantation. 67:1999;S226.
20. Suthanthiran M.et al. Immunosuppressants: cellular and molecular mechanisms of action. Am. J. Kidney Dis. 28:1996;159-172.
21. Kahan B.D. FTY720: a new immunosuppressive agent with novel mechanism(s) of action. Transplant. Proc. 30:1998;2210-2213.
22. Xu M.et al. Effect of peritransplant FTY720 alone or in combination with posttransplant FK506 in a rat model of cardiac allotransplantation. Transplant. Proc. 29:1997;2964-2966.
23. Xu M.et al. FTY720 compares with FK506 as rescue therapy in rat heterotopic cardiac transplantation. Transplant. Proc. 30:1998;2221-2222.
24. Chueh S.C.et al. Induction of tolerance toward rat cardiac allografts by treatment with allochimeric class I MHC antigen and FTY720. Transplantation. 64:1997;1407-1414.
25. Suzuki S.et al. The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720. Clin. Exp. Immunol. 107:1997;103-111.
26. Matsuda S.et al. Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. J. Immunol. 162:1999;3321-3326.
27. Li X.K.et al. FTY720, a novel immunosuppressive agent, enhances upregulation of the cell adhesion molecular ICAM-1 in TNF-α treated human umbilical vein endothelial cells. Transplant. Proc. 29:1997;1265-1266.
28. Luster A.D. Chemokines - chemotactic cytokines that mediate inflammation. New Engl. J. Med. 338:1998;436-445.
29. Brunkhorst R.et al. Human safety and pharmacology of FTY720. Transplantation. 67:1999;S153.
30. Neumeyer H.et al. Human pharmacokinetics of FTY720. Transplantation. 67:1999;S204.